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Abstract
AIM: To analyze differences in patients’ clinical course, 
we compared two regimes of either preemptive therapy 
or prophylaxis after liver transplantation.
METHODS: This retrospective study was reviewed 
and approved by the institutional review board of 
the University of Leipzig. Cytomegalovirus (CMV) 
prophylaxis with valganciclovir hydrochloride for liver 
transplant recipients was replaced by a preemptive 
strategy in October 2009. We retrospectively compared 
liver transplant recipients 2 years before and after 
October 2009. During the first period, all patients 
received valganciclovir daily. During the second period 
all patients included in the analysis were treated 
following a preemptive strategy. Outcomes included 
one year survival and therapeutic intervention due to 
CMV viremia or infection.
RESULTS: Between 2007 and 2010 n  = 226 patients 
underwent liver transplantation in our center. n  = 
55 patients were D+/R- high risk recipients and were 
excluded from further analysis. A further 43 patients 
had to be excluded since CMV prophylaxis/preemptive 
strategy was not followed although there was no 
clinical reason for the deviation. Of the remaining 
128 patients whose data were analyzed, 60 received 
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incidence and the severity of CMV infections. However, 
appropriate substances for prophylaxis have major 
side effects including myelodepression. Therefore, 
preemptive therapy has been proposed as an alternative 
regimen[1,5-7]. Preemptive therapy aims at suppressing 
viral replication after detection of CMV viremia, but 
prior to the onset of clinical symptoms. Antiviral therapy 
is then initiated in order to prevent clinically relevant 
infections[8-13]. However, to date, there is no strong 
clinical evidence indicating superiority of one regimen in 
liver transplant recipients over the other. To accumulate 
more evidence on the clinical course in patients after 
liver transplantation, we used retrospective data to 
compare preemptive therapy to prophylaxis during the 
liver transplantation program of the university hospital 
of Leipzig.
MATERIALS AND METHODS
The study was approved by the Institutional Review Board 
of the university of Leipzig (No. 122-12-16042012). 
Prophylaxis with valganciclovir hydrochloride had 
been the standard treatment for liver transplant recipients 
in our center irrespective of their CMV serological status. 
Since patients presented with serious side effects 
including pancytopenia, prophylaxis was replaced by 
a preemptive strategy in October 2009. To assess 
differences in safety and efficacy of the two regimens, 
we retrospectively compared all liver transplant 
recipients two years before and after October 2009 
during hospital stay after liver transplantation. Data 
on mortality was collected up to one year after 
transplantation. All patients treated according to the 
prophylaxis regimen received 450mg valganciclovir 
twice daily. If necessary doses were adapted to 
renal function. For patients treated after October 
2009, only high-risk seronegative recipients, who 
received an organ from a seropositive donor (D+/R-), 
received prophylaxis and therefore all D+/R- patients 
in both groups were excluded from analysis. For both 
regimens, CMV polymerase chain reaction (PCR) was 
performed twice weekly. When PCR was positive, all 
patients in both groups were treated with ganciclovir 
for at least 14 d, whether or not there were clinical 
symptoms.
The data collected included baseline data, antibody 
patterns against CMV for donor and recipients (D/R), 
viremia during the intensive care unit (ICU) stay and 
occurrence of CMV infections. Furthermore, occurrence 
of sepsis, thrombocytopenia [platelet count < 50 giga 
particles (GPT)/L], leukocytopenia (white blood cells 
< 4 GPT/L) and anemia (hematocrit < 30%) starting 
72 h after ICU admission was documented. LabMELD 
(Model of end stage liver disease) score was calculated 
for each patient on the day of transplantation. All MELD 
points were calculated retrospectively using validated 
laboratory data. Mortality data were collected during 
initial hospital stay and at day 28, day 90 and 1 year 
after transplantation. All patients received the same 
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prophylaxis and 68 were treated following a preemptive 
strategy. The difference in overall mortality was not 
significant, nor was it significant for one-year mortality 
where it was 10% (95%CI: 8%-28%, P  = 0.31) higher 
for the preemptive group. No significant differences in 
blood count abnormalities or the incidence of sepsis 
and infections were observed other than CMV. In 
total, 19 patients (14.7%) received ganciclovir due 
to CMV viremia and/or infections. Patients who were 
treated according to the preemptive algorithm had a 
significantly higher rate risk of therapeutic intervention 
with ganciclovir [n  = 16 (23.5%) vs  n  = 3 (4.9%), P  = 
0.003)]. 
CONCLUSION: These data suggest that CMV prophylaxis 
is superior to a preemptive strategy in patients undergoing 
liver transplantation.
Key words: Transplantation; Liver; Cytomegalovirus; 
Preemptive; Prophylaxis; Valganciclovir; Therapy 
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This retrospective study compares a preemptive 
therapy to prophylaxis for cytomegalovirus (CMV) 
infection in 128 patients after liver transplantation (LTx). 
CMV infections are frequent and increase morbidity 
and mortality so that preventive strategies are routine 
procedures. The one-year mortality did not differ 
significantly between the preemptive (n  = 68) and 
prophylaxis (n  = 60) groups, though it was 10% 
(95%CI: 8%-28%, P  = 0.31) higher for the former. 
Preemptive patients had a significantly higher rate 
of intervention with ganciclovir (23.5% vs  4.9%, P  
= 0.003). Our data suggest that CMV prophylaxis is 
superior to a preemptive strategy after LTx.
Simon P, Sasse M, Laudi S, Petroff D, Bartels M, Kaisers UX, 
Bercker S. Two strategies for prevention of cytomegalovirus 
infections after liver transplantation. World J Gastroenterol 2016; 
22(12): 3412-3417  Available from: URL: http://www.wjgnet.
com/1007-9327/full/v22/i12/3412.htm  DOI: http://dx.doi.
org/10.3748/wjg.v22.i12.3412
INTRODUCTION
Patients who undergo immunosuppressive therapy 
after solid organ transplantation are at higher risk for 
opportunistic bacterial, fungal, and viral infections. 
Infections with cytomegalovirus (CMV) are frequent and 
have been shown to increase morbidity and mortality in 
particular shortly after transplantation[1]. Estimates for 
the incidence of CMV infections after liver transplantation 
(LTx) range from 22% to 29%[1-3]. Therefore, strategies 
for preventing CMV infections are a routine proce-
dure after solid organ transplantation[4]. Prophylaxis 
with antiviral substances leads to a reduction in the 
standard immunosuppression with mycophenolate 
mofetil, steroids (tapered within 8 wk) and tacrolimus 
(days 1-14 FK506 level 10 ng/mL, days 15-28 8 ng/
mL and continuing with 5 ng/mL). In the event of 
severe infection or side effects, immunosuppressive 
therapy was chosen by the physicians on an individual 
basis. 
Statistical analysis
Data were collected in an Excel 2010 spreadsheet 
(Microsoft Corp., Redmond, United States). Statistical 
analysis was performed using SPSS Statistics 20.0 
(SPSS GmbH Software, Munich, Germany) and R 
version 3.1.0. (R Foundation for Statistical Computing, 
Vienna, Austria). Survival analyses were performed 
using a log-rank test with the R package “survival”. 
Categorical data are expressed as absolute or relative 
frequencies and the χ2 or Fisher’s exact test was used 
for inferential statistics depending on the number of 
expected counts. The confidence interval for differences 
in proportions makes use of a Wilson confidence 
interval. Continuous data or categorical ones with fewer 
than six levels are expressed as mean and standard 
deviation and a t-test was used for comparing groups. 
If categorical data has five or fewer levels, then median 
and interquartile range are presented and differences 
between groups are compared using the Wilcoxon-
Mann-Whitney U test. A P value of less 0.05 was 
considered to be statistically significant.
RESULTS
Between 2007 and 2010 n = 226 patients underwent 
liver transplantation in our center. n = 55 patients 
were D+/R- high risk recipients and were excluded 
from further analysis. A further 43 patients had to be 
excluded since CMV prophylaxis/preemptive strategy 
was not followed although there was no clinical reason 
for the deviation. These 43 patients do not differ 
markedly from the remainder with respect to sex, age 
or labMELD. Of the remaining 128 patients whose data 
were analyzed, 60 received prophylaxis and 68 were 
treated following a preemptive strategy. 
Mean age of all analyzed patients was 54 ± 10 
years, 90 patients were male and 38 were female (Table 
1). The mean labMELD score before transplantation 
was 18.5 ± 9.4. At day 1 after transplantation patients 
had a mean APACHE Ⅱ (Acute Physiology And Chronic 
Health Evaluation Ⅱ) score of 14.2 ± 6.7 and a SOFA 
(simplified organ failure assessment) of 9.1 ± 4.0.
Mortality did not differ significantly between the 
groups (Figure 1). At one year, the mortality was 
18/60 (30%, 95%CI: 20%-43%) for the prophylaxis 
strategy and 27/67 (40%, 95%CI: 29%-52%) for 
the preemptive strategy, where one censored case 
accounts for the denominator of 67 instead of 68 
patients. However, this difference did not reach 
significance (P = 0.31). 
There was a nonhomogeneous distribution of 
donors and recipients serologic CMV patterns in our 
series, which was not significant. We found 22% D-/R- 
in the preemptive group compared with 10% in the 
prophylaxis group (Table 1). 
There were no significant differences in blood count 
abnormalities or the incidence of sepsis and infections 
other than CMV (Table 2). In total 19 patients (15%) 
received ganciclovir due to CMV viremia and/or 
infections. The therapy started 29 ± 20 d after 
transplantation on average and lasted for a mean of 
18 ± 12 d. Patients who were treated according to the 
preemptive algorithm had a significantly higher rate 
risk of therapeutic intervention with ganciclovir [n = 
16 (24%) vs n = 3 (5%), P = 0.005]. From these 19 
patients 16 patients (84.0%) had clinical symptoms 
allegeable by CMV in context of the viremia [prophylaxis 
n = 2 (12.5%), preemptive therapy n = 14 (87.5%)].
3414 March 28, 2016|Volume 22|Issue 12|WJG|www.wjgnet.com
Table 1  Patient demographics  n (%)
All 
(n  = 128)
Prophylaxis 
(n  = 60)
Preemptive 
therapy 
(n  = 68)
P  value
Age (yr) 54 ± 10 52 ± 12 56 ± 8.5 0.04
Sex
   Male 90 (70) 42 (70) 48 (71) 1.00
   Female 38 (30) 18 (30) 20 (29)
Weight (kg)   80 ± 16   81 ± 13   79 ± 19 0.52
SOFA   9.1 ± 4.0   8.8 ± 3.8   9.4 ± 4.3 0.34
APACHE II 14.2 ± 6.7 13.3 ± 5.5 15.0 ± 7.5 0.13
Lab. MELD at 
Transplantation
18.5 ± 9.4 18.8 ± 8.8 18.2 ± 9.9 0.73
CMV-status D/R 0.24
   -/- 19 (17)   5 (10) 14 (22)
   -/+ 33 (29) 16 (33) 17 (27)
   +/+ 60 (54) 28 (57) 32 (51)
   +/- Excluded
Data are expressed as mean ± SD or n (%). Complete CMV-status was 
unavailable for 16 patients, but was known not to be +/-. D/R: Donor/
receptor; CMV: Cytomegalovirus; Lab.MELD: Model of end stage liver 
disease.
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Figure 1  Survival curve. Mortality did not differ significantly between the 
groups.
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most centers tend to use prophylaxis at least in high-
risk patients[16]. 
All told, there is no strong evidence from randomized 
studies indicating which of the two strategies is 
superior after liver transplantation. Accordingly, several 
authors consider both treatment options to be similarly 
effective[8,11,12,20-22]. 
Positive effects of a preemptive strategy can be the 
reduction of side effects and costs. When compared to 
no preventive strategy at all, preemptive therapy leads 
to less graft rejection and may improve CMV specific 
cell-mediated immunity and lead to a decreased risk of 
late CMV infections[11,13,23]. On the other hand, the use 
of prophylactic strategies has been shown to reduce 
mortality, the incidence of graft loss and opportunistic 
viral[24], bacterial or fungal infections[25]. Otherwise, 
prophylaxis increases the risk of drug-resistance and 
the incidence of late-onset CMV disease[26]. 
The incidence of CMV infection varies depending 
upon donor and/or recipient serological status[19,27,28]. 
Hodson et al[25] suggested in a systematic review 
of randomized trials, that CMV infections are more 
frequently in sero-negative patients and current 
guidelines suggest antiviral prophylaxis at least in 
D+/R- patients[29,30]. In the presented study, these 
patients have been excluded from analysis. There is 
an imbalance of sero-negative patients between the 
two groups in our study (Table 1) and following the 
above argument, one might have supposed that the 
prophylaxis group was at higher risk of infection. It 
turns out that none of the 19 sero-negative patients in 
the study had CMV viremia/infection, however, so that 
this could not have contributed to our findings.
The presented retrospective study of consecutive 
treatment groups has limitations. Due to the retro-
spective character and lack of randomization, a 
variety of factors such as slight changes in therapeutic 
regimens over-time may have influenced results. On 
the other hand, we demonstrated that groups did not 
differ concerning demographic baseline data, severity 
of liver failure or severity of disease at admission, and 
therefore suggest that our results strongly support 
the hypothesis that the higher incidence of CMV 
viremia was mainly influenced by the introduction of 
a preemptive strategy. Attributing clinical symptoms 
such as diarrhea or elevation of liver enzymes in the 
early course after LTX to CMV remains uncertain as 
there are a broad variety of possible causes. However, 
we suggest that our results support the hypothesis 
that prophylaxis is more effective in preventing CMV 
viremia and infection even in patients with low or mid 
risk for CMV infection. In conclusion, we demonstrated 
a significantly lower rate of CMV viremia/infection with 
prophylaxis when compared to a preemptive strategy. 
Our data indicate that prophylaxis might be superior 
to a preemptive strategy. To confirm this hypothesis, 
randomized prospective trials in liver transplant 
recipients are needed.
DISCUSSION
We retrospectively compared the effects of a 
preemptive and a prophylactic strategy to prevent 
CMV infections during the early phase after liver trans-
plantation. We could demonstrate that a preemptive 
strategy was associated with significantly more 
episodes of CMV viremia/infections in patients with 
mid/low risk without evidence for more side effects of 
the antiviral substances. 
Recommendations for prevention of CMV infections 
in solid organ transplantation are heterogeneous 
and rather difficult to interpret. There are a few 
prospective randomized studies comparing both 
regimens after kidney transplantation. Kliem et 
al[15] demonstrated that prophylaxis reduced the 
incidence of CMV infections by 65% and the authors 
suggest that prophylaxis might improve long-term 
graft survival and recommend limiting preemptive 
strategies to low-risk patients. In a series of 296 
kidney transplant patients, there was a reduction of 
CMV infections by 28 percentage points in the group 
who received prophylactic therapy (38.7% vs 11%, 
P < 0.0001)[16]. On the other hand, Reischig et al[17] 
and Khoury et al[18] found a similar incidence of CMV 
infections in both groups (6% vs 9%, P = 0.567) and 
therefore suggested a comparable efficacy of both 
strategies. Gerna et al[19] performed a controlled, 
randomized, open-label study in 21 children after liver 
transplantation and did not report any CMV disease, 
irrespective of the procedure. A recent Cochrane 
analysis concluded that data is not yet sufficient to 
recommend one strategy over the other prophylaxis or 
preemptive strategies[14].
For adult liver transplant recipients, data from 
randomized studies are not available. In clinical practice 
there is a broad variety of strategies concerning the 
selection of substances, the timing and the duration of 
either prophylaxis or preemptive strategies. However, 
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Table 2  Infection/blood count abnormalities  n  (%)
All 
(n  = 128)
Prophylaxis 
(n  = 60)
Preemptive 
therapy 
(n  = 68)
P  value
Re - LTx   17 (13) 10 (17)   7 (10) 0.31
Infection   86 (71) 40 (69) 46 (72) 0.84
Sepsis   63 (52) 30 (52) 33 (52) 1.00
Thrombocytopenia   69 (57) 32 (55) 37 (58) 0.86
(PLT < 50 Gpt/L; 
> 72 h post-LTx
Leukocytopenia   38 (31) 15 (26) 23 (36) 0.25
(WBC < 4 Gpt/L; 
> 72 h post-LTx)
Anaemia 114 (93) 54 (93) 60 (94) 1.00
(Hct < 30%; 
> 72 h post-LTx)
GPT: Giga particles; LTx:  Liver transplantation; PLT: Platelet count; WBC: 
White blood cells; Hct: Haematocrit.
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COMMENTS
Background
Patients after solid organ transplantation who undergo immunosuppressive 
therapy are at higher risk for infections with cytomegalovirus. They are 
frequent and have been shown to increase morbidity and mortality, particularly 
during the early stages after liver transplantation. Therefore, strategies for 
preventing cytomegalovirus (CMV) infections are a routine procedure after 
liver transplantation. Prophylaxis with antiviral substances leads to a reduction 
in the incidence and the severity of CMV infections. Preemptive therapy aims 
at suppression of viral replication after detection of CMV viremia and prior to 
the onset of clinical symptoms. The authors compared preemptive therapy to 
prophylaxis during the liver transplantation program of the university hospital 
of Leipzig to analyze differences in the clinical course in patients after liver 
transplantation.
Research frontiers
There is no strong evidence from randomized studies demonstrating which 
of the strategies is superior after liver transplantation. Accordingly, several 
authors consider both treatment options to be similarly effective. The authors 
demonstrated a significantly lower rate of CMV viremia/infection using 
prophylaxis when compared to a preemptive strategy. The data indicate that 
prophylaxis might be superior to a preemptive strategy.
Innovations and breakthroughs
Current study found a lower incidence of CMV viremia/infection with prophylaxis 
compared to a preemptive strategy without significant differences in blood count 
abnormalities or the incidence of infections and differences in mortality at any 
time. These data indicate that prophylaxis might be superior to a preemptive 
strategy.
Applications
The data indicate that prophylaxis might be superior to a preemptive strategy. 
To confirm this hypothesis randomized prospective trials in liver transplant 
recipients are needed.
Peer-review
The topic has a great interest given the lack of studies in this field in liver 
transplant recipients. Nevertheless the higher rate of seronegative patients in 
the pre-emptive group could explain the higher rate of infections in this group. 
It would be interesting to include some data regarding duration of treatment in 
both groups and regarding the specific period of time after transplant in which 
the CMV infection occurred (early infection vs late infection).
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